Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEDM for Neoadjuvant Chemotherapy Response Assessment
NCT04625517Phase 4Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by UT Southwestern Medical Center. Primary endpoints: Sensitivity of Predicting Pathologic Complete Response for CEDM, Sensitivity of Predicting Pathologic Complete Response for Mammography and 4 more. Started Jan 2020; status: terminated.
Beyond the preview
Go deeper on NCT04625517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625517.